Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Albert Oriol et al.|New England Journal of Medicine|2023Cited by 719
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphomaChava Perry, Irit Avivi, Efrat Luttwak et al.|Blood Advances|2021Cited by 170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyRon Ram, Ronen Ben‐Ami, David Hagin et al.|Transplantation and Cellular Therapy|2021Cited by 164
A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Arnon Nagler, Irit Avivi et al.|Cancer|2012Cited by 108
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studiesDan Cohen, Einat Even‐Sapir, Efrat Luttwak et al.|European Journal of Nuclear Medicine and Molecular Imaging|2021Cited by 58